Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

Development of Biocompatible Cu(I)-Microdevices for Bioorthogonal Uncaging and Click Reactions

  • Van de L’Isle, Melissa
  • Croke, Stephen
  • Valero Griñán, María Teresa|||0000-0002-3625-311X
  • Unciti-Broceta, Asier
Transition-metal-catalyzed bioorthogonal reactions emerged a decade ago as a novel strategy to implement spatiotemporal control over enzymatic functions and pharmacological interventions. The use of this methodology in experimental therapy is driven by the ambition of improving the tolerability and PK properties of clinically-used therapeutic agents. The preclinical potential of bioorthogonal catalysis has been validated in vitro and in vivo with the in situ generation of a broad range of drugs, including cytotoxic agents, anti-inflammatory drugs and anxiolytics. In this article, we report our investigations towards the preparation of solid-supported Cu(I)-microdevices and their application in bioorthogonal uncaging and click reactions. A range of ligand-functionalized polymeric devices and off-on Cu(I)-sensitive sensors were developed and tested under conditions compatible with life. Last, we present a preliminary exploration of their use for the synthesis of PROTACs through CuAAC assembly of two heterofunctional mating units., European Union’s Horizon 2020 research and innovation program under the Marie Sklodowska-Curie Grant Agreement no. 765497 (THERACAT), EU Horizon 2020 research and innovation programme under the Marie Skłodowska Curie grant agreement No. 749299
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

In Cellulo Bioorthogonal Catalysis by Encapsulated AuPd Nanoalloys: Overcoming Intracellular Deactivation

  • Rubio Ruiz, Belén|||0000-0003-4720-6578
  • Ortega Liébana, M. Carmen
  • Valero Griñán, María Teresa|||0000-0002-3625-311X
Bioorthogonal metallocatalysis has opened up a xenobiotic route to perform nonenzymatic catalytic transformations in living settings. Despite their promising features, most metals are deactivated inside cells by a myriad of reactive biomolecules, including biogenic thiols, thereby limiting the catalytic functioning of these abiotic reagents. Here we report the development of cytocompatible alloyed AuPd nanoparticles with the capacity to elicit bioorthogonal depropargylations with high efficiency in biological media. We also show that the intracellular catalytic performance of these nanoalloys is significantly enhanced by protecting them following two different encapsulation methods. Encapsulation in mesoporous silica nanorods resulted in augmented catalyst reactivity, whereas the use of a biodegradable PLGA matrix increased nanoalloy delivery across the cell membrane. The functional potential of encapsulated AuPd was demonstrated by releasing the potent chemotherapy drug paclitaxel inside cancer cells. Nanoalloy encapsulation provides a novel methodology to develop nanoreactors capable of mediating new-to-life reactions in cells., UK Research & Innovation (UKRI), Engineering & Physical Sciences Research Council (EPSRC) EP/N021134/1, ERC (Advanced Grant CADENCE) ERC-2016-ADG-742684, European Commission European Commission Joint Research Centre H2020-MSCA-IF-2014-658833 H2020-MSCA-IF-2018-841990 H2020-MSCA-IF-2016-749299 H2020-MSCA-IF-2019-895664, Spanish Government RTI2018-099019-A-I00
Digibug. Repositorio Institucional de la Universidad de Granada
Publication Artículo científico (JournalArticle)

A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability

  • Temps, Carolin
  • Valero Griñán, María Teresa|||0000-0002-3625-311X
C. Temps thanks the CMVM of the University of Edinburgh (Principal's scholarship). D. Lietha acknowledges support from the Spanish Ministry of Science, Innovation, and Universities for the Spanish State Research Agency Retos Grant RTI2018-099318-B-I00, cofunded by the European Regional Development Fund (FEDER). E.R. Webb, J.C. Dawson, and K.G. Macleod are funded by CRUK. J.R. Luque-Ortega acknowledges support from the Molecular Interactions Facility funds at the CIB-CSIC. T. Valero is funded by H2020-MSCA-IF-2016-749299. R. Contreras-Montoya thanks the support from the Vice-Rectorate for Research of the University of Granada. X-F. Li and B-Z. Qian are funded by a CRUK Career Development Fellowship (C49791/A17367). B-Z. Qian also acknowledges support from an ERC Starting Grant (716379). C. Schoenherr, M.C. Frame, and V.G. Brunton are funded by CRUK Programme Grant C157/A15703. N.O. Carragher and A. Unciti-Broceta are grateful to the CMVM of the University of Edinburgh and Wellcome Trust for financial support (ISSF3). We thank the ALBA synchrotron-radiation facility (Barcelona, Spain) for providing access for X-ray diffraction data collection and the XALOC beamline staff for their assistance., Despite the approval of several multikinase inhibitors that target SRC and the overwhelming evidence of the role of SRC in the progression and resistance mechanisms of many solid malignancies, inhibition of its kinase activity has thus far failed to improve patient outcomes. Here we report the small molecule eCF506 locks SRC in its native inactive conformation, thereby inhibiting both enzymatic and scaffolding functions that prevent phosphorylation and complex formation with its partner FAK. This mechanism of action resulted in highly potent and selective pathway inhibition in culture and in vivo. Treatment with eCF506 resulted in increased antitumor efficacy and tolerability in syngeneic murine cancer models, demonstrating significant therapeutic advantages over existing SRC/ABL inhibitors. Therefore, this mode of inhibiting SRC could lead to improved treatment of SRC-associated disorders. Significance: Small molecule–mediated inhibition of SRC impairing both catalytic and scaffolding functions confers increased anticancer properties and tolerability compared with other SRC/ABL inhibitors., Spanish Ministry of Science, Innovation, and Universities RTI2018-099318-B-I00, European Commission, Cancer Research UK, Molecular Interactions Facility funds at the CIB-CSIC, Vice-Rectorate for Research of the University of Granada, CRUK Career Development Fellowship C49791/A17367, European Research Council (ERC) 716379, CRUK Programme Grant C157/A15703, CMVM of the University of Edinburgh, Wellcome Trust, European Commission H2020-MSCA-IF-2016-749299
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A conformation selective mode of inhibiting SRC improves drug efficacy and tolerability, Running title: New mode of inhibiting SRC improves drug properties

  • Temps, Caroline
  • Lietha, Daniel
  • Webb, Emily R.
  • Li, Xue-Feng
  • Dawson, John C.
  • Muir, Morwenna
  • Macleod, Kenneth G.
  • Valero, Teresa
  • Munro, Alison F.
  • Contreras-Montoya, Rafael
  • Luque-Ortega, Juan Román
  • Fraser, Craig
  • Beetham, Henry
  • Schoenherr, Christina
  • Lopalco, Maria
  • Arends, Mark J.
  • Frame, Margaret C.
  • Qian, Bin-Zhi
  • Brunton, Valerie G.
  • Carragher, Neil O.
  • Unciti-Broceta, Asier
14 p.-5 fig., Despite the approval of several multikinase inhibitors that target SRC and the overwhelming evidence of the role of SRC in the progression and resistance mechanisms of many solid malignancies, inhibition of its kinase activity has thus far failed to improve patient outcomes. Here we report the small molecule eCF506 locks SRC in its native inactive conformation, thereby inhibiting both enzymatic and scaffolding functions that prevent phosphorylation and complex formation with its partner FAK. This unprecedented mechanism of action resulted in highly potent and selective pathway inhibition, in culture and in vivo. Treatment with eCF506 resulted in increased antitumor efficacy and tolerability in syngeneic murine cancer models, demonstrating significant therapeutic advantages over existing SRC/ABL inhibitors. Therefore, this novel mode of inhibiting SRC could lead to improved treatment of SRC-associated disorders., C.T. thanks the CMVM of the University of Edinburgh (Principal's scholarship). D.L. acknowledges support from the Spanish Ministry of Science, Innovation and Universities for the Spanish State Research Agency Retos Grant RTI2018-099318-B-I00, cofunded by the European Regional Development Fund (FEDER). E.R.W., J.C.D. and K.G.M. are funded by CRUK. J.R.L.O. acknowledges support from the Molecular Interactions Facility funds at the CIB-CSIC. T.V. is funded by H2020-MSCA-IF-2016-749299. RCM thanks the support from the Vice Rectorate for Research of the University of Granada. X.-F.L. and B.-Z.Q. are funded by a CRUK Career Development Fellowship (C49791/A17367). B.-Z.Q. also acknowledges support from an ERC Starting Grant (716379). C.S, M.C.F. and V.G.B are funded by CRUK Programme Grant C157/A15703. N.O.C. and A.U.B are grateful to the CMVM of the University of Edinburgh and Wellcome Trust for financial support (ISSF3)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bioorthogonal uncaging of cytotoxic paclitaxel through Pd nanosheet-hydrogel frameworks

  • Pérez‐López, Ana M.
  • Rubio‐Ruiz, Belén
  • Valero, Teresa
  • Contreras Montoya, Rafael
  • Álvarez de Cienfuegos, Luis
  • Sebastián, Víctor
  • Santamaría, Jesús
  • Unciti-Broceta, Asier
The promising potential of bioorthogonal catalysis in biomedicine is inspiring incremental efforts to design strategies that regulate drug activity in living systems. To achieve this, it is not only essential to develop customized inactive prodrugs and biocompatible metal catalysts but also the right physical environment for them to interact and enable drug production under spatial and/or temporal control. Toward this goal, here, we report the first inactive precursor of the potent broad-spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable in cell culture and labile to Pd catalysts. This new prodrug is effectively uncaged in cancer cell culture by Pd nanosheets captured within agarose and alginate hydrogels, providing a biodegradable catalytic framework to achieve controlled release of one of the most important chemotherapy drugs in medical practice. The compatibility of bioorthogonal catalysis and physical hydrogels opens up new opportunities to administer and modulate the mobility of transition metal catalysts in living environs., We thank EPSRC (Healthcare Technology Challenge Award, no. EP/N021134/1) and ERC (Advanced Grant CADENCE, no. ERC-2016-ADG-742684) for funding. B.R.-R. and T.V. thank the EC for an MSC Fellowship (H2020-MSCA-IF-2014-658833 and H2020-MSCA-IF-2016-749299, respectively). R.C.M. is grateful for the support of the Vicerrectorate of Research of University of Granada. R.C.-M. and L.A.C. thank Junta de Andalucı́a (Spain) for funding project P12-FQM-790. L.A.C. thanks the Ministerio de Ciencia, Innovación y Universidades, for a Salvador de Madariaga visiting professor fellowship (PRX18/00017) and the Agencia Estatal de Investigación (Ministerio de Economia y Competitividad) and the European Regional Development Fund for cofunding project FIS2017-85954-R. V.S. acknowledges the financial support from Ministerio de Ciencia, Innovación y Universidades, Programa Retos Investigación, Proyecto REF: RTI2018-099019-A-I00., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Bioorthogonal Uncaging of Cytotoxic Paclitaxel through Pd Nanosheet-Hydrogel Frameworks

  • Pérez-López, A.M.
  • Rubio-Ruiz, B.
  • Valero, T.
  • Contreras-Montoya, R.
  • Álvarez de Cienfuegos, L.
  • Sebastián, Víctor
  • Santamaría, Jesús
  • Unciti-Broceta, A.
The promising potential of bioorthogonal catalysis in biomedicine is inspiring incremental efforts to design strategies that regulate drug activity in living systems. To achieve this, it is not only essential to develop customized inactive prodrugs and biocompatible metal catalysts but also the right physical environment for them to interact and enable drug production under spatial and/or temporal control. Toward this goal, here, we report the first inactive precursor of the potent broad-spectrum anticancer drug paclitaxel (a.k.a. Taxol) that is stable in cell culture and labile to Pd catalysts. This new prodrug is effectively uncaged in cancer cell culture by Pd nanosheets captured within agarose and alginate hydrogels, providing a biodegradable catalytic framework to achieve controlled release of one of the most important chemotherapy drugs in medical practice. The compatibility of bioorthogonal catalysis and physical hydrogels opens up new opportunities to administer and modulate the mobility of transition metal catalysts in living environs.